Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Masimo reports robust Q4 earnings, eyes new product launches

Masimo's Q4 2022 earnings call highlighted strong financial performance, growth projections for 2023, and a focus on innovation and regulatory advancements. While facing challenges like supply chain issues and legal disputes, the company remains optimistic about opportunities in new product launches and revenue growth drivers. Overall, Masimo is poised for continued success in the healthcare market.

Masimo reports robust Q1 earnings, navigates challenges with strategic focus

Masimo's Q1 performance reflects strong revenue growth and product innovation, underpinned by a focus on healthcare technology and wearables for chronic illness monitoring.
While facing challenges such as litigation costs and regulatory clearances, Masimo maintains its financial guidance for 2023, signaling stability and strategic resilience.
The company's emphasis on new product launches, diverse pricing strategies, and global market expansion positions it well to capitalize on opportunities in the healthcare sector.

Masimo faces revenue challenges in Q2 but eyes rebound

Masimo's Q2 performance was impacted by revenue challenges in Healthcare and non-healthcare segments, leading to a revised revenue guidance for 2023.
The company is focusing on expense control measures, new product opportunities, and pricing discipline to drive profitability and rebound in business segments.
Despite challenges, Masimo remains optimistic about market opportunities in telehealth, consumer health, and the potential for revenue growth from products like Stork.
Ongoing litigation with Apple and uncertainties in customer order patterns pose challenges, but the company is implementing strategies to address these issues.

Masimo reports solid Q3 earnings, eyes growth in consumer health

Masimo's Q3 performance showcased strong revenue but challenges in sensor utilization recovery. The company's innovative products and expansion into consumer health signal growth potential. Addressing challenges in revenue guidance and market competition will be key focus areas for future success.

Masimo reports robust Q4 earnings, legal wins and growth opportunities

Masimo's strong Q4 performance and strategic focus on healthcare and hearables/wearables growth position the company well for 2024.
Legal victories in Apple litigation and FDA clearances for innovative products underscore Masimo's commitment to innovation and protecting its intellectual property.
While facing challenges in legal proceedings and product clearances, Masimo has opportunities to drive revenue growth through product innovation and market expansion.

Masimo reports strong Q1 earnings, plans consumer business separation

Masimo's Q1 2024 Earnings Call showcased robust financial performance, strategic revenue diversification, and plans for enhancing shareholder value through potential separation of the consumer business. While facing challenges in operational transitions and financial metrics scrutiny, the company is well-positioned for growth and value creation.

Masimo reports robust Q3 performance and outlines growth opportunities

Masimo's Q3 2024 earnings call showcased strong financial performance, strategic reviews, and growth initiatives. While facing challenges in margin progression and potential disruptions, the company is poised for growth with opportunities in revenue expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Hospital La Fe in Valencia, Spain is expanding its telehealth and telemonitoring program with the Masimo W1™ advanced health tracking watch.

Hospital La Fe Expands Telehealth Program with Masimo W1™ for Preoperative Patients

NEW YORK--(BUSINESS WIRE)--Masimo and the Clinton Foundation hosted an in-person roundtable today to discuss the overdose and addiction crisis.

Masimo and Clinton Foundation Host Roundtable Addressing Overdose and Addiction Crisis

IRVINE, Calif.--(BUSINESS WIRE)--Denon PerL™ and PerL Pro™ True Wireless Earbuds feature Masimo Adaptive Acoustic Technology™ (AAT™) for a truly personalized listening experience.

Masimo Expands Into the Personalized Hearables Market with Denon PerL™ True Wireless Earbuds, Featuring Masimo Adaptive Acoustic Technology™ (AAT™)

Two influential proxy advisory firms are backing activist Politan Capital Management's quest for two board seats at Masimo , arguing the candidates would bring experience and perspective to the medical device maker's five-person board.

Activist Politan gets fresh backing for boardroom challenge at Masimo

Masimo's (MASI) advanced monitoring technologies and solutions attract new customers looking for better patient care, using remote and centralized surveillance, and seamless data transfer to EMRs.

Masimo (MASI) Inks Deals for Patient Monitoring Technologies

Proxy advisory firm Institutional Shareholder Services (ISS) on Tuesday backed Politan Capital Management in a boardroom challenge at medical device maker Masimo Corp by recommending shareholders elect both of the activist's candidates.

ISS backs both Politan directors in boardroom challenge at Masimo -report

IRVINE, Calif.--(BUSINESS WIRE)--The Board of Directors of Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) today issued a letter to stockholders in connection with the Company's Annual Meeting of Stockholders to be held on June 26, 2023. The letter outlines the importance of Masimo's mission-driven innovation to its financial success and how Politan Capital Management (“Politan”) nominee Quentin Koffey's ill-informed plans to meddle in Masimo's R&D strategy endanger the Compan.

Masimo Board of Directors Highlights Value of Company's Mission-Driven Innovation in Letter to Stockholders

IRVINE, Calif.--(BUSINESS WIRE)--Community Health System (CHS) of Fresno, CA is adopting a variety of advanced Masimo technologies system-wide.

Community Health System Expands Use of Multiple Masimo Technologies, System-wide

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), a 9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today issued a letter to shareholders from its highly qualified nominees Michelle Brennan and Quentin Koffey in connection with the Annual Meeting of Stockholders (the “Annual Meeting”), scheduled for June 26, 2023. The full text of the letter can be found below: Dear Fellow Shareholders, We have greatly enjoyed the o.

Politan Nominees Michelle Brennan and Quentin Koffey Send Letter to Masimo Shareholders

NEUCHATEL, Switzerland--(BUSINESS WIRE)--The Department of Anesthesiology at Lausanne University Hospital (CHUV) is making Masimo W1™ part of its pre-surgical patient assessment program.

Lausanne University Hospital (CHUV) Anesthesiology Department Adopts Masimo W1™ for Use in Preoperative Patient Assessment

Masimo's (MASI) Radius VSM is expected to equip any hospital bed with comprehensive monitoring and offer more personalized care without additional bedside equipment.

Masimo's (MASI) New FDA Approval to Boost Patient Monitoring

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) today announced that Joe Kiani, founder, Chairman and Chief Executive Officer of Masimo, unconditionally, irrevocably and permanently waived his right to assert that a Change in Control has occurred pursuant to Section 9(iii) of his employment agreement unless there occurs a change in the Company's Board in which the individuals who constituted the Board at the beginning of the twelve (12) month perio.

Masimo Chairman and CEO Joe Kiani Waives Rights Under Director Change-in-Control Provision

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), a 9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today commented on the Company's recent announcement that it would authorize expanding its Board and adding Politan nominee Michelle Brennan – contingent on the reelection of all incumbent Masimo directors at the upcoming Annual Meeting of Stockholders (the “Annual Meeting”). Quentin Koffey, Managing Partner and Chief.

Politan Comments on Masimo's Recent Board Announcement

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 11:00 a.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global technology company that develops and produces a wide array of industry-leading mon.

Masimo to Present in Jefferies Healthcare Conference

Positive earnings surprises for Masimo Corporation in FY 2023 are less likely, taking into account Masimo's unchanged full-year financial guidance. It will be tough for Masimo's shares to witness a meaningful re-rating, considering recent developments relating to legal cases against Apple Inc. and an activist investor's attempt to appoint new directors. I maintain a Hold rating for Masimo Corporation, as I don't see any favorable catalysts for the stock in the near term.

Masimo: Staying Neutral Following Unchanged Guidance And Recent Developments

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Radius VSM™, a patient-worn, continuous multi-parameter vital signs monitor, has received FDA 510(k) clearance.

Masimo Announces FDA 510(k) Clearance of Radius VSM™

IRVINE, Calif.--(BUSINESS WIRE)--On June 2, 2023, Masimo Corporation (“Masimo”) issued the following press release in connection with Masimo's 2023 Annual Meeting of Stockholders, which corrects Masimo's press release issued earlier on June 2, 2023 (the “Prior Release”). The Prior Release stated that stockholders do not need to vote for Ms. Brennan to add her to Masimo's Board of Directors. The following press release removes this statement and clarifies that Masimo's Board of Directors has com.

CORRECTING and REPLACING Masimo Board of Directors Authorizes Appointment of Michelle Brennan as Sixth Director Pending Stockholder Approval of Board Expansion and Election of Company Nominees

IRVINE, Calif.--(BUSINESS WIRE)--The Board of Directors of Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) today announced its commitment to appoint Michelle Brennan as the Company's sixth director, pending stockholder approval of the proposal to expand the Board of Directors to seven and the election of the Company's highly qualified director nominees, H Michael Cohen and Julie Shimer, Ph.D. Ms. Brennan was nominated by Politan Capital Management (“Politan”). Masimo stockholders.

Masimo Board of Directors Authorizes Appointment of Michelle Brennan as Sixth Director Pending Stockholder Approval of Board Expansion and Election of Company Nominees

IRVINE, Calif.--(BUSINESS WIRE)--The Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) Board of Directors today issued a letter to stockholders to set the record straight on the many highly misleading and inaccurate claims recently published by Politan Capital Management (“Politan”). Politan's reckless and unprincipled willingness to distort the truth in pursuit of its agenda shows its founder and nominee Quentin Koffey is not to be trusted to serve on Masimo's Board of Directors. T.

Masimo Board of Directors Sets the Record Straight on False and Misleading Claims

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI) today filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its Annual Meeting of Stockholders to be held on June 26, 2023. The presentation outlines why the management team and Board of Directors are well-positioned to continue delivering strong returns to all stockholders and details the risk that Politan Capital Management (“Politan”) and its nominee Que.

Masimo Files Investor Presentation Highlighting Track Record of Success, Compelling Strategy, Responsive Governance Changes and Risks Posed by Quentin Koffey's Agenda

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), a 9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today released a presentation highlighting why independent oversight and greater accountability are urgently needed on the Masimo Board. Politan also responded to multiple false and misleading claims made by the Company in its recent proxy materials and letter to shareholders. Shareholders can support change by voting.

Politan Releases Investor Presentation Detailing Why New Directors Are Needed on the Masimo Board and Responds to Company's Disingenuous Claims

Masimo's (MASI) latest expansion to its HEOS platform will likely revolutionize health and wellness tracking by allowing connected care as consumers become tetherless and smartphone-less.

Masimo's (MASI) Platform Expansion to Boost Patient Monitoring

Hologic

Integer Holdings

The Zacks Medical - Instruments industry is growing on rising demand for digital health. HOLX, MASI and ITGR are set to gain the most.

3 Medical Instruments Stocks to Buy Amid Industry Challenges

IRVINE, Calif.--(BUSINESS WIRE)--The Masimo HEOS® platform is expanding to enable connection to the Masimo secure health cloud for 4 million devices from Denon and other brands.

Masimo Announces Major Expansion of the HEOS® Platform

The heavy selling pressure might have exhausted for Masimo (MASI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

News for Masimo Stock (MASI)